Houghton Mifflin Harcourt Company (HMHC) Stock Competitors & Peer Comparison
See (HMHC) competitors and their performances in Stock Market.
Peer Comparison Table: Education & Training Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HMHC | $21.03 | +0.00% | 0 | 12.54 | $1.68 | N/A |
| EDU | $47.03 | -1.40% | 7.5B | 12.99 | $3.62 | +2.55% |
| TAL | $9.81 | -1.90% | 6B | 9.70 | $1.01 | N/A |
| LAUR | $38.20 | +2.30% | 5.3B | 23.44 | $1.63 | N/A |
| GHC | $1,183.27 | +1.14% | 5.1B | 20.93 | $56.65 | +0.62% |
| LOPE | $152.65 | +2.93% | 4B | 16.27 | $9.38 | N/A |
| ATGE | $106.64 | +1.49% | 3.9B | 15.71 | $6.79 | N/A |
| LRN | $90.44 | +2.11% | 3.8B | 10.97 | $8.23 | N/A |
| UTI | $48.24 | +2.59% | 2.7B | 62.62 | $0.77 | N/A |
| PRDO | $34.43 | +3.55% | 2.2B | 12.25 | $2.81 | +1.76% |
Stock Comparison
HMHC vs EDU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, EDU has a market cap of 7.5B. Regarding current trading prices, HMHC is priced at $21.03, while EDU trades at $47.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas EDU's P/E ratio is 12.99. In terms of profitability, HMHC's ROE is +0.01%, compared to EDU's ROE of +0.11%. Regarding short-term risk, HMHC is less volatile compared to EDU. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check EDU's competition here
HMHC vs TAL Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, TAL has a market cap of 6B. Regarding current trading prices, HMHC is priced at $21.03, while TAL trades at $9.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas TAL's P/E ratio is 9.70. In terms of profitability, HMHC's ROE is +0.01%, compared to TAL's ROE of +0.15%. Regarding short-term risk, HMHC is less volatile compared to TAL. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check TAL's competition here
HMHC vs LAUR Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, LAUR has a market cap of 5.3B. Regarding current trading prices, HMHC is priced at $21.03, while LAUR trades at $38.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas LAUR's P/E ratio is 23.44. In terms of profitability, HMHC's ROE is +0.01%, compared to LAUR's ROE of +0.25%. Regarding short-term risk, HMHC is less volatile compared to LAUR. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check LAUR's competition here
HMHC vs GHC Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, GHC has a market cap of 5.1B. Regarding current trading prices, HMHC is priced at $21.03, while GHC trades at $1,183.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas GHC's P/E ratio is 20.93. In terms of profitability, HMHC's ROE is +0.01%, compared to GHC's ROE of +0.06%. Regarding short-term risk, HMHC is less volatile compared to GHC. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check GHC's competition here
HMHC vs LOPE Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, LOPE has a market cap of 4B. Regarding current trading prices, HMHC is priced at $21.03, while LOPE trades at $152.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas LOPE's P/E ratio is 16.27. In terms of profitability, HMHC's ROE is +0.01%, compared to LOPE's ROE of +0.30%. Regarding short-term risk, HMHC is less volatile compared to LOPE. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check LOPE's competition here
HMHC vs ATGE Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, ATGE has a market cap of 3.9B. Regarding current trading prices, HMHC is priced at $21.03, while ATGE trades at $106.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas ATGE's P/E ratio is 15.71. In terms of profitability, HMHC's ROE is +0.01%, compared to ATGE's ROE of +0.17%. Regarding short-term risk, HMHC is less volatile compared to ATGE. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check ATGE's competition here
HMHC vs LRN Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, LRN has a market cap of 3.8B. Regarding current trading prices, HMHC is priced at $21.03, while LRN trades at $90.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas LRN's P/E ratio is 10.97. In terms of profitability, HMHC's ROE is +0.01%, compared to LRN's ROE of +0.20%. Regarding short-term risk, HMHC is less volatile compared to LRN. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check LRN's competition here
HMHC vs UTI Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, UTI has a market cap of 2.7B. Regarding current trading prices, HMHC is priced at $21.03, while UTI trades at $48.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas UTI's P/E ratio is 62.62. In terms of profitability, HMHC's ROE is +0.01%, compared to UTI's ROE of +0.13%. Regarding short-term risk, HMHC is less volatile compared to UTI. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check UTI's competition here
HMHC vs PRDO Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, PRDO has a market cap of 2.2B. Regarding current trading prices, HMHC is priced at $21.03, while PRDO trades at $34.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas PRDO's P/E ratio is 12.25. In terms of profitability, HMHC's ROE is +0.01%, compared to PRDO's ROE of +0.17%. Regarding short-term risk, HMHC is less volatile compared to PRDO. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check PRDO's competition here
HMHC vs MH Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, MH has a market cap of 2B. Regarding current trading prices, HMHC is priced at $21.03, while MH trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas MH's P/E ratio is 5.24. In terms of profitability, HMHC's ROE is +0.01%, compared to MH's ROE of +0.05%. Regarding short-term risk, HMHC is less volatile compared to MH. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check MH's competition here
HMHC vs STRA Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, STRA has a market cap of 1.8B. Regarding current trading prices, HMHC is priced at $21.03, while STRA trades at $80.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas STRA's P/E ratio is 12.83. In terms of profitability, HMHC's ROE is +0.01%, compared to STRA's ROE of +0.08%. Regarding short-term risk, HMHC is less volatile compared to STRA. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check STRA's competition here
HMHC vs LINC Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, LINC has a market cap of 1.7B. Regarding current trading prices, HMHC is priced at $21.03, while LINC trades at $52.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas LINC's P/E ratio is 56.27. In terms of profitability, HMHC's ROE is +0.01%, compared to LINC's ROE of +0.12%. Regarding short-term risk, HMHC is less volatile compared to LINC. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check LINC's competition here
HMHC vs DAO Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, DAO has a market cap of 1.5B. Regarding current trading prices, HMHC is priced at $21.03, while DAO trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas DAO's P/E ratio is 89.86. In terms of profitability, HMHC's ROE is +0.01%, compared to DAO's ROE of -0.03%. Regarding short-term risk, HMHC is less volatile compared to DAO. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check DAO's competition here
HMHC vs AFYA Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, AFYA has a market cap of 1.4B. Regarding current trading prices, HMHC is priced at $21.03, while AFYA trades at $15.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas AFYA's P/E ratio is 8.73. In terms of profitability, HMHC's ROE is +0.01%, compared to AFYA's ROE of +0.16%. Regarding short-term risk, HMHC is less volatile compared to AFYA. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check AFYA's competition here
HMHC vs PXED Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, PXED has a market cap of 1.2B. Regarding current trading prices, HMHC is priced at $21.03, while PXED trades at $34.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas PXED's P/E ratio is 9.97. In terms of profitability, HMHC's ROE is +0.01%, compared to PXED's ROE of +0.21%. Regarding short-term risk, HMHC is less volatile compared to PXED. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check PXED's competition here
HMHC vs APEI Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, APEI has a market cap of 1B. Regarding current trading prices, HMHC is priced at $21.03, while APEI trades at $56.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas APEI's P/E ratio is 30.01. In terms of profitability, HMHC's ROE is +0.01%, compared to APEI's ROE of +0.14%. Regarding short-term risk, HMHC is less volatile compared to APEI. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check APEI's competition here
HMHC vs COUR Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, COUR has a market cap of 999.7M. Regarding current trading prices, HMHC is priced at $21.03, while COUR trades at $5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas COUR's P/E ratio is 16.87. In terms of profitability, HMHC's ROE is +0.01%, compared to COUR's ROE of -0.10%. Regarding short-term risk, HMHC is less volatile compared to COUR. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check COUR's competition here
HMHC vs ARCE Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, ARCE has a market cap of 927.4M. Regarding current trading prices, HMHC is priced at $21.03, while ARCE trades at $13.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas ARCE's P/E ratio is -73.58. In terms of profitability, HMHC's ROE is +0.01%, compared to ARCE's ROE of +0.02%. Regarding short-term risk, HMHC is more volatile compared to ARCE. This indicates potentially higher risk in terms of short-term price fluctuations for HMHC.Check ARCE's competition here
HMHC vs QSG Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, QSG has a market cap of 822.3M. Regarding current trading prices, HMHC is priced at $21.03, while QSG trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas QSG's P/E ratio is 5.54. In terms of profitability, HMHC's ROE is +0.01%, compared to QSG's ROE of +0.24%. Regarding short-term risk, HMHC is less volatile compared to QSG. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check QSG's competition here
HMHC vs REDU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, REDU has a market cap of 730.3M. Regarding current trading prices, HMHC is priced at $21.03, while REDU trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas REDU's P/E ratio is -23.04. In terms of profitability, HMHC's ROE is +0.01%, compared to REDU's ROE of +0.15%. Regarding short-term risk, HMHC is less volatile compared to REDU. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check REDU's competition here
HMHC vs UDMY Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, UDMY has a market cap of 677.3M. Regarding current trading prices, HMHC is priced at $21.03, while UDMY trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas UDMY's P/E ratio is -92.60. In terms of profitability, HMHC's ROE is +0.01%, compared to UDMY's ROE of -0.03%. Regarding short-term risk, HMHC is more volatile compared to UDMY. This indicates potentially higher risk in terms of short-term price fluctuations for HMHC.Check UDMY's competition here
HMHC vs GOTU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, GOTU has a market cap of 636.6M. Regarding current trading prices, HMHC is priced at $21.03, while GOTU trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas GOTU's P/E ratio is -7.31. In terms of profitability, HMHC's ROE is +0.01%, compared to GOTU's ROE of -0.30%. Regarding short-term risk, HMHC is less volatile compared to GOTU. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check GOTU's competition here
HMHC vs VSTA Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, VSTA has a market cap of 394M. Regarding current trading prices, HMHC is priced at $21.03, while VSTA trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas VSTA's P/E ratio is 4.22. In terms of profitability, HMHC's ROE is +0.01%, compared to VSTA's ROE of +0.10%. Regarding short-term risk, HMHC is more volatile compared to VSTA. This indicates potentially higher risk in terms of short-term price fluctuations for HMHC.Check VSTA's competition here
HMHC vs VTRU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, VTRU has a market cap of 304.2M. Regarding current trading prices, HMHC is priced at $21.03, while VTRU trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas VTRU's P/E ratio is 15.91. In terms of profitability, HMHC's ROE is +0.01%, compared to VTRU's ROE of +0.05%. Regarding short-term risk, HMHC is more volatile compared to VTRU. This indicates potentially higher risk in terms of short-term price fluctuations for HMHC.Check VTRU's competition here
HMHC vs SKIL-WT Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, SKIL-WT has a market cap of 138.5M. Regarding current trading prices, HMHC is priced at $21.03, while SKIL-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas SKIL-WT's P/E ratio is N/A. In terms of profitability, HMHC's ROE is +0.01%, compared to SKIL-WT's ROE of +10.24%. Regarding short-term risk, HMHC is less volatile compared to SKIL-WT. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check SKIL-WT's competition here
HMHC vs CHGG Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, CHGG has a market cap of 113.6M. Regarding current trading prices, HMHC is priced at $21.03, while CHGG trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas CHGG's P/E ratio is -25.37. In terms of profitability, HMHC's ROE is +0.01%, compared to CHGG's ROE of -0.63%. Regarding short-term risk, HMHC is less volatile compared to CHGG. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check CHGG's competition here
HMHC vs BEDU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, BEDU has a market cap of 66.8M. Regarding current trading prices, HMHC is priced at $21.03, while BEDU trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas BEDU's P/E ratio is -0.55. In terms of profitability, HMHC's ROE is +0.01%, compared to BEDU's ROE of -1.03%. Regarding short-term risk, HMHC is less volatile compared to BEDU. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check BEDU's competition here
HMHC vs LFS Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, LFS has a market cap of 59.6M. Regarding current trading prices, HMHC is priced at $21.03, while LFS trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas LFS's P/E ratio is 76.00. In terms of profitability, HMHC's ROE is +0.01%, compared to LFS's ROE of +0.36%. Regarding short-term risk, HMHC is less volatile compared to LFS. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check LFS's competition here
HMHC vs STG Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, STG has a market cap of 54M. Regarding current trading prices, HMHC is priced at $21.03, while STG trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas STG's P/E ratio is 1.04. In terms of profitability, HMHC's ROE is +0.01%, compared to STG's ROE of +0.40%. Regarding short-term risk, HMHC is less volatile compared to STG. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check STG's competition here
HMHC vs ONE Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, ONE has a market cap of 51.3M. Regarding current trading prices, HMHC is priced at $21.03, while ONE trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas ONE's P/E ratio is N/A. In terms of profitability, HMHC's ROE is +0.01%, compared to ONE's ROE of +2.36%. Regarding short-term risk, HMHC is less volatile compared to ONE. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check ONE's competition here
HMHC vs YOUL Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, YOUL has a market cap of 43.9M. Regarding current trading prices, HMHC is priced at $21.03, while YOUL trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas YOUL's P/E ratio is 6.02. In terms of profitability, HMHC's ROE is +0.01%, compared to YOUL's ROE of +0.29%. Regarding short-term risk, HMHC is less volatile compared to YOUL. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check YOUL's competition here
HMHC vs AIU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, AIU has a market cap of 37.6M. Regarding current trading prices, HMHC is priced at $21.03, while AIU trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas AIU's P/E ratio is 0.51. In terms of profitability, HMHC's ROE is +0.01%, compared to AIU's ROE of -1.90%. Regarding short-term risk, HMHC is less volatile compared to AIU. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check AIU's competition here
HMHC vs RYET Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, RYET has a market cap of 34.8M. Regarding current trading prices, HMHC is priced at $21.03, while RYET trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas RYET's P/E ratio is -7.92. In terms of profitability, HMHC's ROE is +0.01%, compared to RYET's ROE of -10.11%. Regarding short-term risk, HMHC is less volatile compared to RYET. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check RYET's competition here
HMHC vs YQ Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, YQ has a market cap of 21.2M. Regarding current trading prices, HMHC is priced at $21.03, while YQ trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas YQ's P/E ratio is -1.54. In terms of profitability, HMHC's ROE is +0.01%, compared to YQ's ROE of -0.46%. Regarding short-term risk, HMHC is less volatile compared to YQ. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check YQ's competition here
HMHC vs GEHI Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, GEHI has a market cap of 18.3M. Regarding current trading prices, HMHC is priced at $21.03, while GEHI trades at $13.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas GEHI's P/E ratio is -0.24. In terms of profitability, HMHC's ROE is +0.01%, compared to GEHI's ROE of -0.90%. Regarding short-term risk, HMHC is less volatile compared to GEHI. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check GEHI's competition here
HMHC vs AACG Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, AACG has a market cap of 16.4M. Regarding current trading prices, HMHC is priced at $21.03, while AACG trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas AACG's P/E ratio is -5.15. In terms of profitability, HMHC's ROE is +0.01%, compared to AACG's ROE of -0.90%. Regarding short-term risk, HMHC is less volatile compared to AACG. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check AACG's competition here
HMHC vs GNS Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, GNS has a market cap of 16.3M. Regarding current trading prices, HMHC is priced at $21.03, while GNS trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas GNS's P/E ratio is -0.25. In terms of profitability, HMHC's ROE is +0.01%, compared to GNS's ROE of -0.37%. Regarding short-term risk, HMHC is less volatile compared to GNS. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check GNS's competition here
HMHC vs EDTK Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, EDTK has a market cap of 15.8M. Regarding current trading prices, HMHC is priced at $21.03, while EDTK trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas EDTK's P/E ratio is -1.77. In terms of profitability, HMHC's ROE is +0.01%, compared to EDTK's ROE of -0.19%. Regarding short-term risk, HMHC is less volatile compared to EDTK. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check EDTK's competition here
HMHC vs IH Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, IH has a market cap of 14.2M. Regarding current trading prices, HMHC is priced at $21.03, while IH trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas IH's P/E ratio is 5.70. In terms of profitability, HMHC's ROE is +0.01%, compared to IH's ROE of +0.08%. Regarding short-term risk, HMHC is less volatile compared to IH. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check IH's competition here
HMHC vs TEDU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, TEDU has a market cap of 12.2M. Regarding current trading prices, HMHC is priced at $21.03, while TEDU trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas TEDU's P/E ratio is -2.40. In terms of profitability, HMHC's ROE is +0.01%, compared to TEDU's ROE of -0.05%. Regarding short-term risk, HMHC is less volatile compared to TEDU. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check TEDU's competition here
HMHC vs BTCT Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, BTCT has a market cap of 9.9M. Regarding current trading prices, HMHC is priced at $21.03, while BTCT trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas BTCT's P/E ratio is -0.87. In terms of profitability, HMHC's ROE is +0.01%, compared to BTCT's ROE of -0.13%. Regarding short-term risk, HMHC is less volatile compared to BTCT. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check BTCT's competition here
HMHC vs VEDU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, VEDU has a market cap of 9.3M. Regarding current trading prices, HMHC is priced at $21.03, while VEDU trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas VEDU's P/E ratio is -1.91. In terms of profitability, HMHC's ROE is +0.01%, compared to VEDU's ROE of -0.43%. Regarding short-term risk, HMHC is less volatile compared to VEDU. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check VEDU's competition here
HMHC vs WAFU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, WAFU has a market cap of 6.9M. Regarding current trading prices, HMHC is priced at $21.03, while WAFU trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas WAFU's P/E ratio is 1.48. In terms of profitability, HMHC's ROE is +0.01%, compared to WAFU's ROE of -0.01%. Regarding short-term risk, HMHC is less volatile compared to WAFU. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check WAFU's competition here
HMHC vs TCTM Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, TCTM has a market cap of 4.9M. Regarding current trading prices, HMHC is priced at $21.03, while TCTM trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas TCTM's P/E ratio is -0.15. In terms of profitability, HMHC's ROE is +0.01%, compared to TCTM's ROE of -2.40%. Regarding short-term risk, HMHC is less volatile compared to TCTM. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check TCTM's competition here
HMHC vs JZ Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, JZ has a market cap of 4.6M. Regarding current trading prices, HMHC is priced at $21.03, while JZ trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas JZ's P/E ratio is -0.13. In terms of profitability, HMHC's ROE is +0.01%, compared to JZ's ROE of -0.44%. Regarding short-term risk, HMHC is less volatile compared to JZ. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check JZ's competition here
HMHC vs TWOU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, TWOU has a market cap of 4.4M. Regarding current trading prices, HMHC is priced at $21.03, while TWOU trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas TWOU's P/E ratio is -0.01. In terms of profitability, HMHC's ROE is +0.01%, compared to TWOU's ROE of -0.88%. Regarding short-term risk, HMHC is less volatile compared to TWOU. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check TWOU's competition here
HMHC vs CLEU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, CLEU has a market cap of 3.5M. Regarding current trading prices, HMHC is priced at $21.03, while CLEU trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas CLEU's P/E ratio is -0.00. In terms of profitability, HMHC's ROE is +0.01%, compared to CLEU's ROE of -0.08%. Regarding short-term risk, HMHC is less volatile compared to CLEU. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check CLEU's competition here
HMHC vs METX Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, METX has a market cap of 3.1M. Regarding current trading prices, HMHC is priced at $21.03, while METX trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas METX's P/E ratio is 0.79. In terms of profitability, HMHC's ROE is +0.01%, compared to METX's ROE of -0.04%. Regarding short-term risk, HMHC is less volatile compared to METX. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check METX's competition here
HMHC vs FEDU Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, FEDU has a market cap of 2.2M. Regarding current trading prices, HMHC is priced at $21.03, while FEDU trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas FEDU's P/E ratio is 16.55. In terms of profitability, HMHC's ROE is +0.01%, compared to FEDU's ROE of +0.07%. Regarding short-term risk, HMHC is more volatile compared to FEDU. This indicates potentially higher risk in terms of short-term price fluctuations for HMHC.Check FEDU's competition here
HMHC vs EEIQ Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, EEIQ has a market cap of 2.1M. Regarding current trading prices, HMHC is priced at $21.03, while EEIQ trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas EEIQ's P/E ratio is -0.62. In terms of profitability, HMHC's ROE is +0.01%, compared to EEIQ's ROE of -0.63%. Regarding short-term risk, HMHC is less volatile compared to EEIQ. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check EEIQ's competition here
HMHC vs MYND Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, MYND has a market cap of 1.7M. Regarding current trading prices, HMHC is priced at $21.03, while MYND trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas MYND's P/E ratio is -0.06. In terms of profitability, HMHC's ROE is +0.01%, compared to MYND's ROE of -9.96%. Regarding short-term risk, HMHC is less volatile compared to MYND. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check MYND's competition here
HMHC vs RYB Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, RYB has a market cap of 1M. Regarding current trading prices, HMHC is priced at $21.03, while RYB trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas RYB's P/E ratio is 1.87. In terms of profitability, HMHC's ROE is +0.01%, compared to RYB's ROE of +0.05%. Regarding short-term risk, HMHC is less volatile compared to RYB. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check RYB's competition here
HMHC vs GV Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, GV has a market cap of 840.7K. Regarding current trading prices, HMHC is priced at $21.03, while GV trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas GV's P/E ratio is -0.13. In terms of profitability, HMHC's ROE is +0.01%, compared to GV's ROE of -1.38%. Regarding short-term risk, HMHC is less volatile compared to GV. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check GV's competition here
HMHC vs GSUN Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, GSUN has a market cap of 638K. Regarding current trading prices, HMHC is priced at $21.03, while GSUN trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas GSUN's P/E ratio is -0.15. In terms of profitability, HMHC's ROE is +0.01%, compared to GSUN's ROE of -1.90%. Regarding short-term risk, HMHC is less volatile compared to GSUN. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check GSUN's competition here
HMHC vs AMBO Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, AMBO has a market cap of 318.5K. Regarding current trading prices, HMHC is priced at $21.03, while AMBO trades at $2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas AMBO's P/E ratio is 1.38. In terms of profitability, HMHC's ROE is +0.01%, compared to AMBO's ROE of +0.39%. Regarding short-term risk, HMHC is less volatile compared to AMBO. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check AMBO's competition here
HMHC vs LXEH Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, LXEH has a market cap of 98.9K. Regarding current trading prices, HMHC is priced at $21.03, while LXEH trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas LXEH's P/E ratio is -0.18. In terms of profitability, HMHC's ROE is +0.01%, compared to LXEH's ROE of -0.15%. Regarding short-term risk, HMHC is less volatile compared to LXEH. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check LXEH's competition here
HMHC vs KIDZW Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, KIDZW has a market cap of 17K. Regarding current trading prices, HMHC is priced at $21.03, while KIDZW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas KIDZW's P/E ratio is N/A. In terms of profitability, HMHC's ROE is +0.01%, compared to KIDZW's ROE of -2.81%. Regarding short-term risk, HMHC is less volatile compared to KIDZW. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check KIDZW's competition here
HMHC vs BTCTW Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, BTCTW has a market cap of 15.5K. Regarding current trading prices, HMHC is priced at $21.03, while BTCTW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas BTCTW's P/E ratio is N/A. In terms of profitability, HMHC's ROE is +0.01%, compared to BTCTW's ROE of -0.13%. Regarding short-term risk, HMHC is less volatile compared to BTCTW. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check BTCTW's competition here
HMHC vs TTEI Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, TTEI has a market cap of 0. Regarding current trading prices, HMHC is priced at $21.03, while TTEI trades at N/A.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas TTEI's P/E ratio is N/A. In terms of profitability, HMHC's ROE is +0.01%, compared to TTEI's ROE of -4.00%. Regarding short-term risk, Volatility data is not available for a full comparison. HMHC has daily volatility of 0.92 and TTEI has daily volatility of N/A.Check TTEI's competition here
HMHC vs HLG Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, HLG has a market cap of 0. Regarding current trading prices, HMHC is priced at $21.03, while HLG trades at $14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas HLG's P/E ratio is 5.29. In terms of profitability, HMHC's ROE is +0.01%, compared to HLG's ROE of +0.11%. Regarding short-term risk, HMHC is more volatile compared to HLG. This indicates potentially higher risk in terms of short-term price fluctuations for HMHC.Check HLG's competition here
HMHC vs METXW Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, METXW has a market cap of 0. Regarding current trading prices, HMHC is priced at $21.03, while METXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas METXW's P/E ratio is N/A. In terms of profitability, HMHC's ROE is +0.01%, compared to METXW's ROE of -0.13%. Regarding short-term risk, HMHC is less volatile compared to METXW. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check METXW's competition here
HMHC vs NEW Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, NEW has a market cap of 0. Regarding current trading prices, HMHC is priced at $21.03, while NEW trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas NEW's P/E ratio is -0.55. In terms of profitability, HMHC's ROE is +0.01%, compared to NEW's ROE of -0.09%. Regarding short-term risk, HMHC is less volatile compared to NEW. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check NEW's competition here
HMHC vs APOL Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, APOL has a market cap of 0. Regarding current trading prices, HMHC is priced at $21.03, while APOL trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas APOL's P/E ratio is N/A. In terms of profitability, HMHC's ROE is +0.01%, compared to APOL's ROE of -0.08%. Regarding short-term risk, HMHC is more volatile compared to APOL. This indicates potentially higher risk in terms of short-term price fluctuations for HMHC.Check APOL's competition here
HMHC vs FHS Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, FHS has a market cap of 0. Regarding current trading prices, HMHC is priced at $21.03, while FHS trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas FHS's P/E ratio is 0.55. In terms of profitability, HMHC's ROE is +0.01%, compared to FHS's ROE of N/A. Regarding short-term risk, HMHC is less volatile compared to FHS. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check FHS's competition here
HMHC vs ZVO Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, ZVO has a market cap of 0. Regarding current trading prices, HMHC is priced at $21.03, while ZVO trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas ZVO's P/E ratio is -0.08. In terms of profitability, HMHC's ROE is +0.01%, compared to ZVO's ROE of -1.07%. Regarding short-term risk, HMHC is less volatile compared to ZVO. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check ZVO's competition here
HMHC vs ZME Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, ZME has a market cap of 0. Regarding current trading prices, HMHC is priced at $21.03, while ZME trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas ZME's P/E ratio is -0.00. In terms of profitability, HMHC's ROE is +0.01%, compared to ZME's ROE of -1.88%. Regarding short-term risk, HMHC is less volatile compared to ZME. This indicates potentially lower risk in terms of short-term price fluctuations for HMHC.Check ZME's competition here
HMHC vs GPX Comparison July 2026
HMHC plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMHC stands at 0. In comparison, GPX has a market cap of 0. Regarding current trading prices, HMHC is priced at $21.03, while GPX trades at $20.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMHC currently has a P/E ratio of 12.54, whereas GPX's P/E ratio is N/A. In terms of profitability, HMHC's ROE is +0.01%, compared to GPX's ROE of +0.03%. Regarding short-term risk, HMHC is more volatile compared to GPX. This indicates potentially higher risk in terms of short-term price fluctuations for HMHC.Check GPX's competition here